FDA rejects Mapi-Viatris long-acting version of Teva’s Copaxone
Positive news for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), after the US Food and Drug Administration (FDA) rejected Viatris and Israeli company Mapi Pharma's 40 mg dose of the long-acting version of…
